斐济由多重耐药脑膜炎奈瑟菌引起的C群脑膜炎球菌病暴发
斐济2016年1月至2018年12月报告96例确诊或可能侵袭性脑膜炎球菌病病例,年发病率从2016年1.8/10万升至2018年5.2/10万。耐环丙沙星的C群多位点序列型4821占比62.1%(41/66)。公共卫生措施包括针对性接种单价C群脑膜炎球菌疫苗,有效控制暴发,后续年份C群脑膜炎病例快速下降。
要点
- 2016—2018年斐济报告96例确诊或可能侵袭性脑膜炎球菌病病例,年发病率由1.8/10万升至5.2/10万。
- 耐环丙沙星的C群多位点序列型4821占62.1%(41/66)。
- 针对性接种单价C群脑膜炎球菌疫苗等公共卫生措施有效控制暴发,后续C群脑膜炎病例快速下降。
核心结论
- 斐济发生由C群脑膜炎奈瑟菌引起的侵袭性脑膜炎球菌病暴发,耐环丙沙星的C群多位点序列型4821为流行株(62.1%,41/66)。
- 包括针对性接种单价C群脑膜炎球菌疫苗在内的公共卫生措施有效控制暴发,后续年份C群脑膜炎病例快速下降。
研究设计与样本
- 建立监测病例定义,使用标准调查表收集数据。
- 在斐济进行细菌鉴定、抗菌药物敏感性试验和PCR,分子检测在澳大利亚维多利亚州墨尔本的微生物诊断中心进行。
- 2016年1月至2018年12月共报告96例确诊或可能侵袭性脑膜炎球菌病病例。
主要发现
- 96例中男性61.5%(59/96)、女性38.5%(37/96),斐济原住民84.4%(81/96),15岁以下儿童70.8%(68/96)。
- 年发病率从2016年1.8/10万升至2018年5.2/10万。
- 耐环丙沙星的C群多位点序列型4821占62.1%(41/66)。
临床怎么用
- 公共卫生措施包括针对性接种单价C群脑膜炎球菌疫苗,有效控制暴发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We describe an outbreak of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup C in Fiji. We created surveillance case definitions and collected data by using standard investigation forms. Bacterial identification, antimicrobial susceptibility testing, and PCR were performed in Fiji. Molecular testing was conducted at the Microbiological Diagnostic Unit in Melbourne, Victoria, Australia. During January 2016-December 2018, a total of 96 confirmed or probable IMD cases were reported. Of case-patients, 61.5% (59/96) were male and 38.5% (37) female, 84.4% (81) were indigenous people of Fiji, and 70.8% (68) were children <15 years of age. Annual incidence increased from 1.8/100,000 population in 2016 to 5.2/100,000 population in 2018. Serogroup C multilocus serotype 4821 that is resistant to ciprofloxacin was prevalent (62.1%, 41/66). Public health measures, which included targeted mass vaccination with monovalent meningitis C vaccine, were effective in controlling the outbreak. We observed a rapid decline in meningitis C cases in subsequent years.
引用
- Strobel AG, Sahukhan A, Ratu A, et al. Meningococcal C Disease Outbreak Caused by Multidrug-Resistant Neisseria meningitidis, Fiji. Emerg Infect Dis. 2025. PMID: 39714270. doi:10.3201/eid3101.240476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。